Introduction
============

As a common complication of tumors, the incidence of cancer related anemia (CRA) ranges from 30% to 90%,[@b1-dddt-13-221] which can be divided into nonchemotherapy- and chemotherapy-induced CRA. Without doubt, the lifestyle quality of these patients is decreased by this condition.[@b2-dddt-13-221] Studies have shown that continuous anemia can cause tachycardia, palpitations, fatigue, respiratory disorders, and other symptoms.[@b3-dddt-13-221] Therefore, the management of anemia in cancer patients is clinically important even though survival is the primary treatment goal. Current mainstream treatment methods include blood transfusions, iron supplements, and erythropoietin (EPO) therapy. However, these treatment methods have some disadvantages; blood transfusion is hampered by a relative shortage of blood donation and the potential survival risk to CRA patients due to transfusion-related complications such as anaphylaxis, iron overload, hemolysis, allogeneic immune response, thrombosis, posttransfusion cardiogenic pulmonary edema, and transfusion-induced viral infections. A careful inspection of a large patient database revealed that cancer patients who received red cell transfusions were more at risk of having venous thrombosis, arterial thrombosis, or of dying.[@b4-dddt-13-221] Cancer patients who underwent surgery and who received red cell transfusions also had an increased mortality.[@b5-dddt-13-221] Iron supplements are usually given for the management of iron deficiency anemia.[@b6-dddt-13-221] However, hemochromatosis or cell injury can occur due to indiscriminate use of oral iron,[@b7-dddt-13-221] and a poor medication compliance rate in these patients was reported, owing to the high frequency of gastrointestinal side effects.[@b8-dddt-13-221] EPO is known to be very effective in improving the hematological response and reducing the need for blood transfusions.[@b9-dddt-13-221]

CRA has increasingly aroused general concern due to its high morbidity and potential influence on the quality of life of CRA patients, with an effective and safe therapeutic method for this condition being of obvious clinical significance. CRA is essentially a type of blood deficiency syndrome, and thus may be treated with traditional Chinese medicine (TCM). In fact, the knowledge and theoretical studies on blood deficiency in TCM are quite mature and have a profound theoretical and practical basis. Based on the relationship between Qi and blood and the relationship between Zangfu and blood generation, TCM formulas supporting Qi and enriching blood have been used to treat blood deficiency syndrome for a long time. In a recent meta-analysis, Zhu et al reported that Huangqi injection could significantly enhance the efficacy of androgens for aplastic anemia.[@b10-dddt-13-221] Another study has also reported the therapeutic effect and safety profile of TCM formulas supporting Qi and enriching blood in the management of CRA,[@b11-dddt-13-221] but the sample sizes in these studies were relative small. Thus we performed this meta-analysis to review systematically randomized controlled trials of TCM supporting Qi and enriching blood for the treatment of CRA in order to clarify in detail the effect and safety of TCM for its treatment.

Materials and methods
=====================

Search strategy
---------------

We performed an electronic search of PubMed, EMBASE, Cochrane, Chinese biological medicine, Chinese Scientific Journal Database, China Wanfang database, and China National Knowledge Infrastructure databases for previous studies on the therapeutic effects and safety of TCM for CRA, with no limitations on language or the publication year, using the following search keywords: "Traditional Chinese medicine supporting Qi and enriching blood" or "Chinese herbology supporting Qi and enriching blood" or "Chinese medicine supporting Qi and enriching blood" and "Cancer related anemia" or "malignant tumor anemia". A Google Scholar search was also performed using these search terms.

Eligibility criteria
--------------------

Randomized controlled trials that provided data on the therapeutic effect and safety of supporting Qi and enriching blood TCMs in patients with CRA compared to a control group who received conventional treatment were eligible for this meta-analysis. In addition, the involved subjects should be solid tumor patients with a hemoglobin level \<110 g/L. Studies in which patients received radiotherapy or chemotherapy during treatment or suffered with a disease that may affect the level of hemoglobin, such as aplastic anemia, were excluded.

Data extraction
---------------

Two reviewers (Zhibo Dang and Xiaoli Liu) independently extracted the following data from each study: first author's surname, publication year, country, the study design, number of patients in the control and TCM groups, male or female, the level of hemoglobin before and after the treatment, the overall therapeutic effect, and any adverse events.

Outcome measurement indexes
---------------------------

### Primary outcome indexes

The level of hemoglobin was set as the primary outcome index.

### Secondary outcome indexes

The overall therapeutic effect and adverse events were set as the secondary outcome indexes.

Statistical analysis
--------------------

All statistical analyses were carried out using RevMan (ver 5.3). An OR was employed for the statistical analysis of the counting data and standardized mean difference or weighted mean difference (MD) were used to analyze statistically the measurement data. Statistical heterogeneity between studies was evaluated using a chi-squared test; *P*\>0.1 and I^2^\<50% were taken to be of low heterogeneity, and a fixed effect model was used. *P*\<0.1 and I^2^\>50% were considered to have statistical heterogeneity; therefore, a random effect model was employed. The heterogeneous source was analyzed and subgroup analysis carried out for factors that may lead to heterogeneity. If heterogeneity arose from low-quality research, sensitivity analysis was carried out. If there was still significant heterogeneity between the two groups, descriptive analysis was used. A *P*-value \<0.05 was considered to be statistically significant, and all tests were two-sided.

Assessment of publications
--------------------------

The methodology excellence of the included studies was evaluated following the guidelines laid down in the Cochrane Handbook for Systematic Reviews. The following factors were taken into account: allocation concealment; blinding of participants; personnel and outcome assessments; incomplete outcome data; random sequence generation; selective reporting; and other potential sources of bias.

A total of 422 papers were obtained from the initial retrieval, of which 260 were excluded due to duplicate publication. A total of 96 papers were obtained after reviewing the title and summary according to the exclusion and inclusion criteria, and 13 were eventually included after a full-text review, which included a total of 1,198 patients ([Figure 1](#f1-dddt-13-221){ref-type="fig"}). In these 13 studies, a different prescription was used in each study, but all of them were typical TCM formula used to improve the Qi and blood deficiency, which is termed anemia in western medicine. In the control group, EPO therapy was used in seven studies, iron supplements were used in three studies, and only antitumor and supportive therapies were used in two studies. One study used either EPO or iron supplements in the control group, but the authors did not clearly clarify which patients used EPO or iron supplement therapy. Eleven studies reported the results of hemoglobin levels and ten studies reported the results of the overall therapeutic effect. All these studies were conducted in Asian patients, one in Japan and the others in P.R. China ([Table 1](#t1-dddt-13-221){ref-type="table"}).

Quality assessment of the selected publications
-----------------------------------------------

The methodology quality of the included studies was relatively low. Five of the studies reported random methods, but all of these studies did not report allocation concealment, blinding of participants, personnel, or the outcome assessments. The outcome data in all of the studies were complete, and there was no selective reporting or bias ([Figure 2](#f2-dddt-13-221){ref-type="fig"}).

Hemoglobin
----------

A total of eleven studies[@b11-dddt-13-221]--[@b21-dddt-13-221] reported changes in hemoglobin levels. A *P*-value \<0.001 and I^2^=97% indicated that there was significant heterogeneity among the studies; thus a random effect model was employed. In the pooled results, the level of hemoglobin in the TCM group was greater than that in the control group (MD=4.57, 95% CI \[1.38, 7.76\], *P*=0.005; I^2^=97%) ([Figure 3](#f3-dddt-13-221){ref-type="fig"}).

Subgroup analysis according to the therapeutic period and therapy method in the control group
---------------------------------------------------------------------------------------------

In order to analyze further the source of significant heterogeneity, subgroup analysis by the follow-up period and therapy method in the control group were separately performed.

First, subgroup analysis was performed according to the different therapeutic period. In the eleven studies, which reported changes in hemoglobin levels, the therapeutic period ranged from 3 weeks to 3 months and was divided into three subgroups: \#30 days for subgroup 1; 31 days to 2 months for subgroup 2; and \>2 months for subgroup 3. However, significant heterogeneity was still found in these subgroups; the level of hemoglobin in the TCM group was significantly greater than that in the control group for subgroup 1 (MD=8.72, 95% CI \[4.62, 12.83\], *P*\<0.000; I^2^=97%) and subgroup 3 (MD=2.92, 95% CI \[1.61, 4.22\], *P*\<0.000; I^2^=0%), but was significantly lower for subgroup 2 (MD=-3.77, 95% CI \[-17.75, 10.21\], *P*=0.60; I^2^=97%) ([Figure 4A](#f4-dddt-13-221){ref-type="fig"}).

Second, subgroup analysis was performed according to the therapy method in the control group. In the eleven studies that reported changes in hemoglobin levels, EPO therapy was employed as the control in six studies, and iron supplements were used in three studies; thus we divided them into EPO and iron supplements subgroups. In a further subgroup analysis, we found that the levels of hemoglobin in the TCM group was significantly higher than that in the control group for both subgroups (EPO subgroup: MD=3.85, 95% CI \[2.18, 5.52\], *P*\<0.000; I^2^=86%; iron supplements subgroup: MD=6.68, 95% CI \[-14.49, 27.85\], *P*=0.54; I^2^=99%) ([Figure 4B](#f4-dddt-13-221){ref-type="fig"}).

Sensitivity analysis
--------------------

We found that the pooled results for comparison of hemoglobin levels between the two groups did not show obvious changes after excluding studies that reported hemoglobin levels one by one, and all of these results achieved statistical significance, thus indicating that the pooled results data had good stability.

The overall therapeutic effect and adverse events
-------------------------------------------------

A total of ten studies[@b12-dddt-13-221]--[@b14-dddt-13-221],[@b17-dddt-13-221]--[@b23-dddt-13-221] reported the results of the overall therapeutic effects. In these studies, the therapeutic effects were summarized as "obvious effect", "moderate effect", "mild effect", and "no efficacy" according to symptoms such as dizziness and facial pallor. However, the former three were classified as "effective" in this review in order to reduce the bias due to no standard criteria for the subjective therapeutic effect. A result of *P*=0.03 and I^2^=51% indicated significant heterogeneity; thus, a random effect model was employed. For the pooled results, a significant improvement in the overall therapeutic effect was found in the TCM group compared to the control group (risk ratio \[RR\]=1.31, 95% CI \[1.18, 1.46\], *P*\<0.000; I^2^=51%) ([Figure 5A](#f5-dddt-13-221){ref-type="fig"}).

A subgroup analysis was also performed according to EPO or iron supplement therapy in the control group, and we found the overall therapeutic effect was significantly better in the TCM group than in the control group for both subgroups (EPO subgroup: RR=1.43, 95% CI \[1.30, 1.58\], *P*\<0.000; I^2^=27%; iron supplement subgroup: RR=1.30, 95% CI \[1.09, 1.56\], *P*=0.004; I^2^=0%), and the heterogeneity was obviously decreased ([Figure 5B](#f5-dddt-13-221){ref-type="fig"}).

A total of four studies reported the results of adverse events, with a result of *P*=0.14 and I^2^=45% indicating low heterogeneity, and a fixed effect model was employed. In the pooled results, the incidence of adverse events was significantly reduced in the TCM group compared to that in the control group (RR=0.54, 95% CI \[0.29, 0.99\], *P*=0.05; I^2^=45%) ([Figure 5C](#f5-dddt-13-221){ref-type="fig"}).

Discussion
==========

As a disease caused by the tumor itself or the treatment, CRA has been reported to be improved or cured by TCM by supporting Qi and enriching the blood. In this meta-analysis, we systematically reviewed studies on the therapeutic effect and safety of TCM formulas for the treatment of CRA in patients not receiving chemoradiotherapy, and a significant improvement in the hemoglobin level was found after TCM treatment compared with that in the control group (MD=4.57, 95% CI \[1.38, 7.76\], *P*=0.005; I^2^=97%). Promising results were also found for the overall therapeutic effect (RR=1.31, 95% CI \[1.18, 1.46\], *P*\<0.000; I^2^=51%). This finding was expected because the evaluation parameters for the overall therapeutic effect in these studies, including symptoms such as facial pallor and dizziness, would theoretically be improved after an increase in hemoglobin levels. However, the significant improvement in hemoglobin levels and the overall therapeutic effect in the TCM group should be cautiously interpreted due to substantial heterogeneity. Therefore, subgroup analysis was performed to explore the source of the heterogeneity, but an opposite changing trend of heterogeneity was found, that had significantly higher heterogeneity in the therapeutic period or in the control method subgroups for hemoglobin levels and obviously decreased heterogeneity for the overall therapeutic effect. Thus, some other factors, such as race or regions, may be responsible for this significant heterogeneity, and further subgroup analysis could not be carried out due to the few number of studies in Caucasians or western countries.

These significant improvements may be attributed to TCM's antitumor actions and the promotion of hemoglobin formation. The effective components of TCM such as *astragalus* polysaccharide and *ginseng* polysaccharide can suppress tumor growth through a variety of mechanisms such as regulating the immune function of the body, inhibition of tumor angiogenesis, induction of tumor cell apoptosis, and induction of differentiation of tumor cells.[@b24-dddt-13-221] For example, Chinese medicine polysaccharide can activate T and B lymphocytes, macrophages, natural killer cells, cytotoxic T cells, dendritic cells, and other immune cells and can stimulate the production of a variety of cytokines including IL1, IL2, IL6, interferon, and tumor necrosis factor that enhance the body's immune function.[@b25-dddt-13-221] On the other hand, Chinese hematinic medicine is sweet, warm, and nurturing. The commonly used hematinic medicines such as *Angelica*, *Radix paeonia alba*, *Radix rehmanniae preparata*, and donkey-hide gelatin have been reported to promote the production of red blood cells and hemoglobin.[@b26-dddt-13-221] In the published studies, the Chinese medicine used in the TCM group included traditional prescription, Chinese patent medicine, and self-prescription medicine, which covered all types of TCM used for the treatment of CRA. The most commonly used Chinese medicines in the studies were *Codonopsis pilosula*, *Astragalus*, and *Angelica*. In animal experiments, subcutaneous injection of *Codonopsis pilosula* decoction obviously increased the number of rabbit red blood cells and hemoglobin levels.[@b27-dddt-13-221] *Astragalus* polysaccharide has an immunomodulatory effect, which can effectively enhance the activity of NK cells, promoting the transformation of T lymphocytes and thus playing an anticancer role. It has been proven that the combination of *Astragalus* polysaccharide with chemotherapy drugs improves the quality of life and survival time of patients with progressive non-small cell lung cancer.[@b28-dddt-13-221] *Angelica* is a major Chinese hematinic medicine, which can repair the hematopoietic function by stimulating the cells and molecules associated with hematopoiesis.[@b29-dddt-13-221] Therefore, a rational combination of these Chinese medicines could theoretically enhance the antitumor effect and improve blood deficiency, and eventually show a significant therapeutic effect on CRA. In the present study, this assertion was proven by the obvious improvement in hemoglobin levels and the overall therapeutic effect in the TCM group compared to that in the control group.

A significant reduction in the incidence of adverse events was also found in the TCM group compared to that in the control group. A total of 14 cases of adverse events were found in this study, including 3 cases of skin rashes or incidence of hypertension; 2 cases of anorexia, allergies or nausea; and 1 case of liver dysfunction or fatigue. All of these adverse events occurred in studies that employed TCM compounds, which is consistent with the findings that the occurrence of adverse events rose with an increase in the TCM composition.[@b30-dddt-13-221] It is worth mentioning that most of the TCM were orally administered, and the incidence of adverse events may be increased by intravenous injection administration; thus, this may be one of the reasons for reduced adverse events in the TCM group.

This study has some limitations. First, our results may have some inherent bias due to an unclear random method, allocation concealment, and blinding in these studies. Second, the sample size of these studies was relatively small, and all of them were limited to Asian populations and regions. A further subgroup analysis was not possible and the pooled results may not be acceptable for other populations in other world regions. Third, there is a lack of uniform efficacy evaluation criteria; hence, the pooled results may have some bias owing to roughly dividing the subjective therapeutic effect into "effective" and "not effective". Finally, since the meta-analysis excluded all reports on patients under chemotherapy or radiotherapy, treatment-related anemia remained outside the scope of our study.

Conclusion
==========

An analysis of current data shows that TCM formulas supporting Qi and enriching blood may be a safe and effective treatment of CRA in patients not receiving chemoradiotherapy and could be considered as an alternative treatment to conventional therapy. There is a certain clinical significance when the risk and cost of blood transfusions, iron supplements, and EPO injections are considered. However, due to the relatively low quality and the small sample sizes of the included studies, the results should be interpreted cautiously. A well-designed, multicenter, and large-sample study is needed to confirm the therapeutic effect and safety of TCM formulas in supporting Qi and enriching the blood for the treatment of CRA in patients not receiving chemoradiotherapy.
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![Characteristics of the randomized trials included in the meta-analysis and used search engines.\
**Abbreviations:** CBM, Chinese biological medicine; CNKI, China National Knowledge Infrastructure; VIP, China Science and Technology Journal Database.](dddt-13-221Fig1){#f1-dddt-13-221}

![Risk of bias summary and methodology quality of the enrolled RCT publications studies.\
**Notes:** red circle, high risk; green circle, low risk; yellow circle, unclear risk.\
**Abbreviation:** RCT, randomized controlled trial.](dddt-13-221Fig2){#f2-dddt-13-221}

![Forest plots of hemoglobin level changes in the enrolled RCT studies, and *I*^2^=97% indicated a significant heterogeneity among the studies (*P*\<0.001).\
**Abbreviation:** RCT, randomized controlled trial.](dddt-13-221Fig3){#f3-dddt-13-221}

![Subgroup analysis was performed with the follow-up period and therapy method in the control group for finding the source of significant heterogeneity.\
**Notes:** (**A**) Analysis of changes in hemoglobin levels in the follow-up period subgroups 1 (\#30 days), 2 (31 days to 2 months), and 3 (\>2 months). (**B**) Analysis of changes in hemoglobin levels between 1) TCM vs EPO and 2) TCM vs iron supplement subgroups.\
**Abbreviations:** EPO, erythropoietin; TCM, traditional Chinese medicine.](dddt-13-221Fig4){#f4-dddt-13-221}

![Analysis of the overall therapeutic effects in this meta-analysis (**A**) in 10 included studies; (**B**) in iron supplement and EPO control studies; (**C**) analysis of adverse events in the pooled results.\
**Abbreviation:** EPO, erythropoietin.](dddt-13-221Fig5){#f5-dddt-13-221}

###### 

The basic characteristics of the included literature

  Subjects                         Publication time   Number of cases (human)   Gender (male/female)   Intervention measures                                                                        Outcome measures                   Course of treatment   
  -------------------------------- ------------------ ------------------------- ---------------------- -------------------------------------------------------------------------------------------- ---------------------------------- --------------------- ----------
                                                                                                                                                                                                                                                             
  Akase et al[@b11-dddt-13-221]    2003               10/15                     Unreported             Danggui Shaoyao Powder                                                                       Chalybeate                         ①③                    8 weeks
  Cheng et al[@b14-dddt-13-221]    2009               33/32                     65/0                   EPO                                                                                          YXS + EPO                          ①②                    12 weeks
  Gu et al[@b16-dddt-13-221]       2010               63/50                     62/51                  Shenfu injection + conventional therapy                                                      Conventional therapy               ①                     3 weeks
  Cai and Zhu[@b12-dddt-13-221]    2016               45/44                     48/41                  Modified Bazhen decoction                                                                    EPO                                ①②③                   8 weeks
  Cai and Wang[@b13-dddt-13-221]   2016               60/60                     64/56                  YXS + conventional therapy                                                                   Conventional therapy               ①②                    30 days
  Du et al[@b15-dddt-13-221]       2015               43/43                     45/41                  Tonifying blood and nourishing Qi decoction + conventional therapy                           Conventional therapy               ①                     3 months
  Ling et al[@b17-dddt-13-221]     2016               50/50                     71/29                  Self-made Chinese herbal decoction + conventional therapy                                    Conventional therapy               ①②                    4 weeks
  Liu and Liao[@b22-dddt-13-221]   2015               44/44                     40/48                  Shen Bai Fu Zheng granule + EPO                                                              EPO                                ①③                    8 weeks
  Liu[@b18-dddt-13-221]            2015               46/46                     60/32                  Self-made warming kidney and invigorating spleen and enriching blood decoction               Folic acid and ferrous succinate   ①②                    30 days
  Lv et al[@b19-dddt-13-221]       2016               56/56                     Unreported             Self-made decoction + EPO                                                                    EPO                                ①②                    4 weeks
  Wang and Li[@b20-dddt-13-221]    2015               40/40                     43/37                  Tonifying kidney strengthening spleen and enriching blood decoction + conventional therapy   Conventional therapy               ①②                    30 days
  Zhang[@b23-dddt-13-221]          2007               50/50                     52/48                  Self-made decoction + EPO                                                                    EPO                                ①                     4 weeks
  Zi[@b21-dddt-13-221]             2016               64/64                     73/55                  Shengxue tiaoyuan granule + EPO                                                              EPO                                ①②③                   6 weeks

**Notes:** ① hemoglobin; ② curative effects; ③ untoward effects.

**Abbreviations:** EPO, erythropoietin; YXS, Yixuesheng capsule; T/C, treatment/control group.
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